Table 1.

Metastatic tumor signature subtype split by primary tumor ER status and grade

Signature	ERa N (%)		P	Gradeb N (%)			P
	Positive 64 (62)	Negative 39 (38)		1 4 (5)	2 35 (43)	3 42 (52)
Genomic grade
GG1	26 (41)	2 (5)		1 (25)	16 (46)	2 (5)
GG3	38 (59)	37 (95)	<0.001	3 (75)	19 (54)	40 (95)	<0.001
70 gene
Low	20 (31)	1 (3)		0 (0)	12 (34)	4 (10)
High	44 (69)	38 (97)	<0.001	4 (100)	23 (66)	38 (90)	0.043
Recurrence score
Low	3 (5)	0 (0)		0 (0)	2 (6)	0 (0)
Intermediate	6 (9)	0 (0)		0 (0)	5 (14)	0 (0)
High	55 (86)	39 (100)	0.015	4 (100)	28 (80)	42 (100)	0.011
CCS
Low	7 (11)	1 (3)		0 (0)	4 (11)	0 (0)
Intermediate	14 (22)	4 (10)		0 (0)	8 (23)	3 (7)
High	43 (67)	34 (87)	0.022	4 (100)	23 (66)	39 (93)	0.015
ROR-S
Low	3 (4)	0 (0)		0 (0)	3 (10)	0 (0)
Medium	29 (48)	8 (21)		1 (25)	15 (48)	8 (19)
High	29 (48)	30 (79)	0.002	3 (75)	13 (42)	34 (81)	0.002
PAM50c
Luminal A	10 (17)	0 (0)		0 (0)	6 (19)	0 (0)
Luminal B	30 (49)	2 (5)		2 (50)	17 (55)	9 (22)
HER2-enriched	19 (31)	12 (32)		1 (25)	6 (19)	14 (33)
Basal-like	2 (3)	24 (63)	<0.001d	1 (25)	2 (7)	19 (45)	<0.001e

NOTE: Correlations were calculated using Wilcoxon/Mann-Whitney (ER) and Spearman rank (Grade) unless otherwise specified. Bold values indicate P < 0.05.

^aPrimary tumor ER status unknown in 6 cases, ≥10% cutoff value for positivity.

^bPrimary tumor grade unknown in 28 cases.

^cReduced numbers (n = 105).

^dThe Fisher exact test.

^eThe Kruskal-Wallis test; n, number of patients.